AMMOL
MCID: ACT193
MIFTS: 54

Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) (AMMOL)

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

MalaCards integrated aliases for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22):

Name: Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) 52 58
Acute Myelomonocytic Leukemia 52 58 17 71
Aml with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) 52 58
Aml M4 52 58
Ammol 52 58
Aml with Inv(16)(p13.1q22) or T(16;16)(p13.1;q22) 52
Acute Myeloblastic Leukemia Type 4 52
Leukemia Myelomonocytic Acute 54
Cbfb-Myh11 52
Aml-M4 52

Characteristics:

Orphanet epidemiological data:

58
acute myelomonocytic leukemia
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

ICD10 32 C92.5
MESH via Orphanet 44 D015479
ICD10 via Orphanet 33 C92.5
UMLS via Orphanet 72 C0023479
UMLS 71 C0023479

Summaries for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

NIH Rare Diseases : 52 Acute myelomonocytic leukemia (AMML) is a cancer that typically develops in the bone marrow and blood of older individuals. AMML is one type of acute myeloid leukemia , a group of blood cancers that occur when the amount of white blood cells increases rapidly. Symptoms of AMML often include fatigue (due to anemia ) or easy bruising or bleeding (due to thrombocytopenia ). The cause of AMML is currently unknown. Treatment typically consists of chemotherapy .

MalaCards based summary : Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22), also known as acute myelomonocytic leukemia, is related to hypereosinophilic syndrome and ring chromosome, and has symptoms including fatigue and fever. An important gene associated with Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) is CBFB (Core-Binding Factor Subunit Beta), and among its related pathways/superpathways are PAK Pathway and PI3K-Akt signaling pathway. The drugs Lenograstim and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are anemia and thrombocytopenia

Related Diseases for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

Diseases related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 209)
# Related Disease Score Top Affiliating Genes
1 hypereosinophilic syndrome 31.0 MYH11 MPO KIT
2 ring chromosome 30.5 KMT2A ETV6
3 acute myeloblastic leukemia with maturation 30.3 KIT FLT3
4 ring chromosome 21 30.2 KMT2A ETV6
5 subleukemic leukemia 30.1 MPO DNTT
6 myeloid sarcoma 29.8 MPO KMT2A KIT FLT3 DNTT
7 atypical chronic myeloid leukemia 29.5 RUNX1 FLT3 ETV6
8 monocytic leukemia 29.4 RUNX1 MPO KMT2A FLT3 CSF1
9 leukemia, acute monocytic 29.0 MPO KMT2A FLT3 CSF1 CREBBP
10 core binding factor acute myeloid leukemia 28.9 RUNX1 KIT FLT3 CSF1R CBFB
11 leukemia 28.9 RUNX1 MYH11 KMT2A KIT FLT3 ETV6
12 precursor t-cell acute lymphoblastic leukemia 28.8 MPO KMT2A FLT3 ETV6 DNTT
13 pancytopenia 28.8 RUNX1 MPO KMT2A KIT FLT3 CSF1
14 myeloproliferative neoplasm 28.8 RUNX1 MPO KMT2A KIT FLT3 ETV6
15 t-cell acute lymphoblastic leukemia 28.6 RUNX1 KMT2A FLT3 ETV6 DNTT
16 myelofibrosis 28.3 RUNX1 MPO KIT FLT3 ETV6 CSF1R
17 acute promyelocytic leukemia 28.1 RUNX1 MPO KMT2A FLT3 ETV6 CSF1R
18 acute leukemia 27.7 RUNX1 MPO KMT2A KIT FLT3 ETV6
19 myeloid leukemia 27.2 RUNX1 MYH11 MPO KMT2A KIT FLT3
20 leukemia, chronic myeloid 26.9 RUNX1 MPO KMT2A KIT FLT3 ETV6
21 chronic myelomonocytic leukemia 26.8 RUNX1 MPO KMT2A KIT FLT3 ETV6
22 myelodysplastic syndrome 26.6 RUNX1 MPO KMT2A KIT FLT3 ETV6
23 leukemia, acute myeloid 26.3 RUNX1 MYH11 MPO KMT2A KIT FLT3
24 leukemia, acute lymphoblastic 26.1 RUNX1 MPO KMT2A KIT FLT3 ETV6
25 chromosomal triplication 10.6
26 47,xyy 10.4
27 partial deletion of the long arm of chromosome 16 10.4 MYH11 CBFB
28 myeloma, multiple 10.4
29 neutropenia 10.4
30 sarcoma 10.3
31 spindle cell sarcoma 10.3
32 acute monoblastic leukemia 10.3
33 refractory anemia 10.3
34 acute myeloid leukemia with minimal differentiation 10.3 MPO FLT3
35 cytogenetically normal acute myeloid leukemia 10.3 KMT2A FLT3
36 leukemia, chronic lymphocytic 10.3
37 leukostasis 10.3
38 trisomy 22 10.3
39 polymorphous low-grade adenocarcinoma 10.3 MYH11 KIT
40 mast-cell sarcoma 10.2 MPO KIT
41 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 10.2
42 deficiency anemia 10.2
43 thrombocytopenia 10.2
44 vasculitis 10.2
45 fragile site, distamycin a type, rare, fra(16)(q22.1) 10.2
46 uremia 10.2
47 mycosis fungoides 10.2
48 lymphoma 10.2
49 gingival overgrowth 10.2
50 hemoglobinuria 10.2

Graphical network of the top 20 diseases related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22):



Diseases related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22)

Symptoms & Phenotypes for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

Human phenotypes related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22):

58 31 (show all 9)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 anemia 58 31 hallmark (90%) Very frequent (99-80%) HP:0001903
2 thrombocytopenia 58 31 hallmark (90%) Very frequent (99-80%) HP:0001873
3 dyspnea 58 31 frequent (33%) Frequent (79-30%) HP:0002094
4 weight loss 58 31 frequent (33%) Frequent (79-30%) HP:0001824
5 pallor 58 31 frequent (33%) Frequent (79-30%) HP:0000980
6 abnormal bleeding 58 31 frequent (33%) Frequent (79-30%) HP:0001892
7 eosinophilia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001880
8 abnormality of the gingiva 58 31 occasional (7.5%) Occasional (29-5%) HP:0000168
9 leukocytosis 58 Very frequent (99-80%)

UMLS symptoms related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22):


fatigue, fever

GenomeRNAi Phenotypes related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) according to GeneCards Suite gene sharing:

26 (show all 26)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.98 FLT3
2 Increased shRNA abundance (Z-score > 2) GR00366-A-116 9.98 FLT3
3 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.98 DNTT
4 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.98 MPO
5 Increased shRNA abundance (Z-score > 2) GR00366-A-138 9.98 DNTT
6 Increased shRNA abundance (Z-score > 2) GR00366-A-145 9.98 DNTT
7 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.98 DNTT
8 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.98 KIT
9 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.98 DNTT KIT MPO
10 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.98 DNTT
11 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.98 KIT
12 Increased shRNA abundance (Z-score > 2) GR00366-A-180 9.98 FLT3
13 Increased shRNA abundance (Z-score > 2) GR00366-A-182 9.98 DNTT
14 Increased shRNA abundance (Z-score > 2) GR00366-A-184 9.98 MPO
15 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.98 FLT3
16 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.98 MPO
17 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.98 KIT
18 Increased shRNA abundance (Z-score > 2) GR00366-A-40 9.98 MPO
19 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.98 MPO
20 Increased shRNA abundance (Z-score > 2) GR00366-A-61 9.98 KIT
21 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.98 MPO
22 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.98 FLT3 MPO
23 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.98 DNTT
24 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.98 KIT
25 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.98 KIT
26 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.98 KIT

MGI Mouse Phenotypes related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22):

45 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.29 CBFB CREBBP CSF1 CSF1R DNTT ETV6
2 cellular MP:0005384 10.27 CBFB CREBBP CSF1 CSF1R ETV6 FLT3
3 hematopoietic system MP:0005397 10.26 CBFB CREBBP CSF1 CSF1R DNTT ETV6
4 growth/size/body region MP:0005378 10.24 CBFB CREBBP CSF1 CSF1R ETV6 FLT3
5 immune system MP:0005387 10.24 CBFB CREBBP CSF1 CSF1R DNTT ETV6
6 cardiovascular system MP:0005385 10.23 CBFB CREBBP CSF1 ETV6 KIT KMT2A
7 endocrine/exocrine gland MP:0005379 10.15 CBFB CREBBP CSF1 CSF1R ETV6 FLT3
8 mortality/aging MP:0010768 10.14 CBFB CREBBP CSF1 CSF1R ETV6 FLT3
9 integument MP:0010771 10.13 CBFB CREBBP CSF1 CSF1R ETV6 KIT
10 craniofacial MP:0005382 10.03 CBFB CREBBP CSF1 CSF1R KIT KMT2A
11 limbs/digits/tail MP:0005371 9.93 CBFB CREBBP CSF1 CSF1R KIT KMT2A
12 liver/biliary system MP:0005370 9.91 CBFB CREBBP CSF1 KIT KMT2A RUNX1
13 neoplasm MP:0002006 9.87 CBFB CREBBP ETV6 FLT3 KIT KMT2A
14 no phenotypic analysis MP:0003012 9.86 CBFB CSF1 CSF1R ETV6 FLT3 KIT
15 muscle MP:0005369 9.85 CREBBP CSF1 KIT KMT2A MPO MYH11
16 normal MP:0002873 9.76 CBFB CREBBP CSF1R DNTT ETV6 KIT
17 respiratory system MP:0005388 9.43 CBFB CREBBP CSF1 KIT MYH11 RUNX1
18 skeleton MP:0005390 9.23 CBFB CREBBP CSF1 CSF1R FLT3 KIT

Drugs & Therapeutics for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

Drugs for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 218)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 4 135968-09-1
2
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
3
Thiotepa Approved, Investigational Phase 4 52-24-4 5453
4 Antilymphocyte Serum Phase 4
5 Alkylating Agents Phase 4
6 Antirheumatic Agents Phase 4
7
Mesna Approved, Investigational Phase 3 3375-50-6 598
8
Idarubicin Approved Phase 3 58957-92-9 42890
9
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
10
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
11
Arsenic trioxide Approved, Investigational Phase 2, Phase 3 1327-53-3 518740
12
Melphalan Approved Phase 3 148-82-3 460612 4053
13
Busulfan Approved, Investigational Phase 3 55-98-1 2478
14
leucovorin Approved Phase 3 58-05-9 6006 143
15
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
16
alemtuzumab Approved, Investigational Phase 2, Phase 3 216503-57-0
17
Etoposide Approved Phase 3 33419-42-0 36462
18
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
19
Thioguanine Approved Phase 3 154-42-7 2723601
20
Carmustine Approved, Investigational Phase 3 154-93-8 2578
21
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
22
Hydroxyurea Approved Phase 3 127-07-1 3657
23
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
24
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
25
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
26
Decitabine Approved, Investigational Phase 3 2353-33-5 451668
27
Azacitidine Approved, Investigational Phase 3 320-67-2 9444
28
Daunorubicin Approved Phase 3 20830-81-3 30323
29
Clofarabine Approved, Investigational Phase 3 123318-82-1 119182
30
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
31
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
32
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
33
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
34
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
35
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
36
midostaurin Approved, Investigational Phase 3 120685-11-2 104937 9829523
37
Histamine Approved, Investigational Phase 3 51-45-6 774
38
Cyproheptadine Approved Phase 3 129-03-3 2913
39
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 444795 5538
40
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
41
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
42 Lintuzumab Investigational Phase 3 166089-32-3
43 Molgramostim Investigational Phase 3 99283-10-0
44
tipifarnib Investigational Phase 3 192185-72-1 159324
45 Antibodies Phase 3
46 Antibodies, Monoclonal Phase 3
47 Immunoglobulins Phase 3
48 Vaccines Phase 3
49 Antineoplastic Agents, Immunological Phase 3
50 Adjuvants, Immunologic Phase 3

Interventional clinical trials:

(show top 50) (show all 257)
# Name Status NCT ID Phase Drugs
1 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
2 Evaluation of the Efficacy of Induction-consolidation Treatment Using a Double Induction in Patients With AML <60 Years Old, Depending on the Percentage of Blasts in the 14 Day, Residual Disease and Leukemic Hematopoietic Cells Unknown status NCT02072811 Phase 3 DAC;CLAG;Consolidation, I HAM cycle;II Consolidation HiDAraC;Consolidation, III HiDAraC cycle
3 A Phase 3, Randomized, Double-Blind, Multicenter Study of Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF in Elderly Patients With AML in First Complete Remission or Adults in Second Complete Remission: A Pivotal Study Unknown status NCT00454168 Phase 3
4 Gemtuzumab Ozogamicin (GO) Monotherapy Versus Standard Supportive Care for Previously Untreated AML in Elderly Patients Who Are Not Eligible for Intensive Chemotherapy: A Randomized Phase II/III Trial (AML-19) of the EORTC-LG and GIMEMA-ALWP Unknown status NCT00091234 Phase 2, Phase 3 gemtuzumab ozogamicin
5 Phase III, Randomized, Multicenter Study to Assess the Efficacy and Safety of HuM195 (Recombinant Humanized Anti-CD33 Monoclonal Antibody) in Combination With Standardized Chemotherapy Compared to Standardized Chemotherapy Alone in the Treatment of Patients With Refractory or First-Relapsed Acute Myelogenous Leukemia (AML) Unknown status NCT00006045 Phase 3 cytarabine;etoposide;mitoxantrone hydrochloride
6 The Value of High Dose Versus Standard Dose ARA-C During Induction and of IL-2 After Intensive Consolidation/Autologous Stem Cell Transplantation in Patients (Age 15-60 Years) With Acute Myelogenous Leukemia. A Randomized Phase II Trial of the EORTC and the GIMEMA-ALWP Unknown status NCT00004128 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide
7 RANDOMIZED PHASE III STUDY OF INDUCTION (ICE VS MICE VS DCE) AND INTENSIVE CONSOLIDATION (IDIA VS NOVIA VS DIA) FOLLOWED BY BONE MARROW TRANSPLANTATION IN ACUTE MYELOGENOUS LEUKEMIA: AML 10 PROTOCOL Unknown status NCT00002549 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mesna;mitoxantrone hydrochloride
8 The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years Unknown status NCT00369317 Phase 3 asparaginase;daunorubicin hydrochloride;cytarabine;thioguanine;etoposide
9 ACUTE MYELOID LEUKAEMIA TRIAL 12 Unknown status NCT00002658 Phase 3 amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
10 A Phase 3 Trial of Systematic Versus Response-adapted Timed-Sequential Induction in Patients With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Completed NCT00428558 Phase 3 Chemotherapy (DAUNORUBICINE-CYTARABINE);Chemotherapy (DAUNORUBICINE-CYTARABINE)
11 A Phase III Study of Flt3 Ligand (Flt3L) Therapy in Acute Myeloid Leukemia (AML) Patients in Remission Completed NCT00006223 Phase 3
12 A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission Completed NCT00093470 Phase 3 Tipifarnib
13 Protocol for Patients With High Risk (Resistant, Refractory, Relapsed or Adverse Cytogenetic) AML Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
14 A Phase III Randomized of Cloretazine™ (VNP40101M) and Cytosine Arabinoside (AraC) in Patients With Acute Myeloid Leukemia in First Relapse Completed NCT00112554 Phase 3 cytarabine;laromustine
15 High-Dose Cytarabine and Idarubicin Induction, High Dose Etoposide and Cyclophosphamide Intensification, Autologous Stem Cell Transplantation and Interleukin-2 Immune Modulation in Previously Untreated De Novo and Secondary Adult Myeloid Leukemia Completed NCT00002945 Phase 3 cyclophosphamide;cytarabine;etoposide;idarubicin;melphalan
16 RANDOMIZED PHASE III STUDY TO EVALUATE THE VALUE OF rHuG-CSF IN INDUCTION AND OF AN ORAL SCHEDULE AS CONSOLIDATION TREATMENT IN ELDERLY PATIENTS WITH ACUTE MYELOGENOUS LEUMEKIA (AML-13 PROTOCOL) Completed NCT00002719 Phase 3 amsacrine;carmustine;cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
17 IDA VS MTZ IN INDUCTION AND INTENSIFICATION TREATMENT OF AML OR MDS IN CHILDREN, A PHASE III RANDOMIZED STUDY Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
18 Gemtuzumab Ozogamicin (GO) Combined With Standard Intensive Chemotherapy Versus Standard Intensive Chemotherapy Alone For Induction/Consolidation In Patients 61-75 Years Old With Previously Untreated AML: A Randomized Phase III Trial (AML-17) Of The EORTC-LG and the GIMEMA-ALWP Completed NCT00052299 Phase 3 cytarabine;etoposide;gemtuzumab ozogamicin;idarubicin;mitoxantrone hydrochloride
19 A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
20 Phase III Study of MDR Modulation With PSC-833 (NSC #648265) Followed by Immunotherapy With rIL-2 (NSC #373364) vs. No Further Therapy in Previously Untreated Patients With AML &gt;60 Years Completed NCT00003190 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar
21 A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults Completed NCT00372593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;gemtuzumab ozogamicin;mitoxantrone hydrochloride
22 A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg®) During Induction Therapy Versus Standard Induction With Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy With Gemtuzumab Ozogamicin (Mylotarg®) or No Additional Therapy For Patients Under Age 61 With Previously Untreated De Novo Acute Myeloid Leukemia (AML) Completed NCT00085709 Phase 3 gemtuzumab ozogamicin;Cytosine arabinoside;Daunomycin
23 A Randomized Trial for Patients With Acute Myeloid Leukemia or High Risk Myelodysplatic Syndrome Aged 60 or Over Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
24 Randomised Induction and Post Induction Therapy in Older Patients (≥61 Years of Age) With Acute Myeloid Leukemia (AML) and Refractory Anemia With Excess Blasts (RAEB, RAEB-t) Completed NCT00121303 Phase 3 cytarabine;daunorubicin hydrochloride;gemtuzumab ozogamicin
25 Treatment of Children With Down Syndrome (DS) and Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Transient Myeloproliferative Disorder (TMD): A Phase III Group-Wide Study Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
26 A Randomized, Placebo-Controlled, Double Blind, Trial of the Administration of the MDR Modulator, Zosuquidar Trihydrochloride (LY335979), During Conventional Induction and Post-Remission Therapy in Patients Greater Than 60 Years of Age With Newly Diagnosed Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts in Transformation or High-Risk Refractory Anemia With Excess Blasts Completed NCT00046930 Phase 3 cytarabine;daunorubicin hydrochloride;zosuquidar trihydrochloride;Placebo
27 Phase III Randomized Study of Induction Chemotherapy With or Without MDR-Modulation With PSC-833 (NSC # 648265, IND # 41121) Followed by Cytogenetic Risk-Adapted Intensification Therapy Followed by Immunotherapy With rIL-2 (NSC # 373364, IND # 1969) vs. Observation in Previously Untreated Patients With AML &lt; 60 Years Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
28 A Programme of Treatment Development for Older Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome Completed NCT00454480 Phase 2, Phase 3 arsenic trioxide;azacitidine;busulfan;clofarabine;cytarabine;daunorubicin hydrochloride;fludarabine phosphate;gemtuzumab ozogamicin;melphalan;tipifarnib
29 A PHASE III STUDY IN CHILDREN WITH UNTREATED ACUTE MYELOGENOUS LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS) Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
30 A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML) Active, not recruiting NCT03306264 Phase 3 ASTX727;Dacogen
31 A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML) Active, not recruiting NCT01307579 Phase 3 Caspofungin Acetate;Fluconazole
32 A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND #101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia (AML) Active, not recruiting NCT00651261 Phase 3 cytarabine;daunorubicin;midostaurin;dexamethasone acetate
33 Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age &gt;/= 60 Years) Active, not recruiting NCT02085408 Phase 3 clofarabine;daunorubicin hydrochloride;cytarabine;decitabine
34 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
35 Treatment of Relapsed Acute Myelogenous Leukemia Consisting of Intermediate Dose Cytosine Arabinoside (ARA-C) Plus Interspaced Continuous Infusion Idarubicin, Followed by Continuous Infusion of Low-Dose ARA-C, A Phase II Study by the EORTC-LCG Unknown status NCT00003758 Phase 2 cytarabine;idarubicin
36 A Phase I/II Study of Lenalidomide in Patients With Chronic Myelomonocytic Leukemia Unknown status NCT01368757 Phase 1, Phase 2 Revlimid
37 Treatment Protocol for Patients With Standard Risk Acute Myelogenous Leukemia and Its Variants: Induction Using High-Dose Cytarabine, Mitoxantrone and Ethyol; Consolidation With Cytarabine and Idarubicin and Maintenance With 13 Cis Retinoic Acid and Alpha Interferon Unknown status NCT00003405 Phase 2 amifostine trihydrate;bromodeoxyuridine;cytarabine;idarubicin;idoxuridine;isotretinoin;mitoxantrone hydrochloride
38 Phase II, Open-Label Study of HuM195 (Humanized Anti-CD33 Monoclonal Antibody) Administered to Patients With Acute Myelogenous Leukemia (AML) Who Are Documented Regimen Failures (RF) of the Control Arm of Study 195-301 Unknown status NCT00006084 Phase 2
39 A Phase II Study of Cloretazine® (VNP40101M) for Elderly Patients With De Novo Poor Risk Acute Myelogenous Leukemia Unknown status NCT00354276 Phase 2 cytarabine;laromustine
40 Clofarabine in Combination With a Standard Remission Induction Regimen (AraC and Idarubicin) in Patients 18-60 Years Old With Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS) : a Phase I-II Study of the EORTC-LG and GIMEMA (AML-14A Trial) Unknown status NCT00838240 Phase 1, Phase 2 clofarabine;cytarabine;idarubicin
41 A Phase I/II Study of Ribavirin and Low-dose Cytarabine Arabinoside (Ara-C) in Acute Myeloid Leukemia (AML) M4 and M5 Subtypes, and AML With High eIF4E Expression Completed NCT01056523 Phase 1, Phase 2 Ribavirin;Cytarabine arabinoside
42 Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia Completed NCT01174043 Phase 2 Erlotinib
43 A Phase II Study of Decitabine in Patients With Chronic Myelomonocytic Leukemia Completed NCT01098084 Phase 2 Decitabine
44 An Open-Label Phase I/II Study of XIAP Antisense AEG35156 Administered to Patients With Refractory/Relapsed AML in Combination With Chemotherapy Completed NCT00363974 Phase 1, Phase 2 XIAP antisense
45 A Phase II Multicenter Open-label Study to Assess the Efficacy of Decitabine in the Treatment of Chronic Myelomonocytic Leukemia Completed NCT01251627 Phase 2 Decitabine
46 A Phase II Study of Gleevec (Imatinib Mesylate) In Patients With BCR-Negative Myeloproliferative Disorders Including Patients With Idiopathic Myelofibrosis With Myeloid Dysplasia or Chronic Myelomonocytic Leukemia Completed NCT00136409 Phase 2 Imatinib mesylate
47 An Open-label, Randomized, Phase 2, Parallel, Dose-Ranging, Multicenter Study of Sotatercept for the Treatment of Patients With Anemia and Low or Intermediate-1 Risk Myelodysplastic Syndromes or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) Completed NCT01736683 Phase 2 Sotatercept
48 Treatment of Post-Transplant Relapse and Persistent Disease in Patients With MDS, CMML and AML With Azacitidine Completed NCT01083706 Phase 2 azacitidine
49 A Phase 2 Study of the AKT Kinase Inhibitor MK-2206 in Patients With Relapsed Refractory Acute Myelogenous Leukemia Completed NCT01253447 Phase 2 Akt inhibitor MK2206
50 A Phase II Study of Sunitinib Malate (Sutent®; SU11248) in Patients With Intermediate-2 or High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Completed NCT00451048 Phase 2 sunitinib malate

Search NIH Clinical Center for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22)

Inferred drug relations via UMLS 71 / NDF-RT 50 :


gemtuzumab
Gemtuzumab ozogamicin

Genetic Tests for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

Anatomical Context for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

MalaCards organs/tissues related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22):

40
Myeloid, Bone, Bone Marrow, Monocytes, T Cells, Skin, Lung

Publications for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

Articles related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22):

(show top 50) (show all 751)
# Title Authors PMID Year
1
Deletion of CBFB in a patient with acute myelomonocytic leukemia (AML M4Eo) and inversion 16. 61 54
15381374 2004
2
A unique AML1 (CBF2A) rearrangement, t(1;21)(p32;q22), observed in a patient with acute myelomonocytic leukemia. 54 61
11566347 2001
3
A novel t(Y;11) translocation with MLL gene rearrangement in a case of acute myelomonocytic leukemia (AML-M4) 61 54
10086743 1999
4
Therapy-related AML after successful chemotherapy with low dose etoposide for virus-associated hemophagocytic syndrome. 54 61
9846019 1998
5
All patients with the T(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders. 54 61
9226152 1997
6
[Detection of MLL gene rearrangement in acute myelomonocytic and monocytic leukemia]. 61 54
10743082 1997
7
Acute leukemia with t(10;11)(p11-p15;q13-q23). 54 61
8616782 1996
8
A novel gene, AF1q, fused to MLL in t(1;11) (q21;q23), is specifically expressed in leukemic and immature hematopoietic cells. 54 61
7833468 1995
9
Acute myelomonocytic leukemia with t(10;11)(p13;q23): heterogeneity of breakpoints at 11q23 and association with recombinase activation. 54 61
7529550 1994
10
Acute myelomonocytic leukemia after treatment with chronic oral etoposide: are MLL and LTG9 genes targets for etoposide? 61 54
7948964 1994
11
Detection of del(16q) using the CBFB-MYH11 translocation dual fusion probe. 61
32202250 2020
12
Acute myelomonocytic leukemia with uncommon morphological features. 61
31915926 2020
13
Penile Ulcer due to Leukemia Cutis-A Rare Diagnosis Not to Be Missed. 61
31913857 2020
14
Bilateral ovarian granulocytic sarcoma as the primary manifestation of acute myelogenous leukemia treated with allogenic stem cell transplantation: A case report. 61
31876710 2019
15
Breast myeloid sarcoma after allogeneic stem cell transplantation for acute myelomonocytic leukemia - case report. 61
31658348 2019
16
Central Nervous System Double Relapse of Acute Promyelocytic Leukemia and Acute Myelomonocytic Leukemia. 61
31929922 2019
17
A Case of Granulocytic Sarcoma or Extramedullary Acute Myelomonocytic Leukemia of the Gallbladder. 61
30352989 2018
18
l-Asparaginase: a feasible therapeutic molecule for multiple diseases. 61
29872609 2018
19
A simplified sheathless cell separation approach using combined gravitational-sedimentation-based prefocusing and dielectrophoretic separation. 61
29725680 2018
20
t(9;19)(q22;p13) in Acute Myelomonocytic Leukemia. 61
29391333 2018
21
Acute Myelomonocytic Leukemia Presenting as Perianal Pain. 61
30598853 2018
22
Orbital myxoma comorbid with acute myelomonocytic leukemia. 61
28812920 2017
23
Clinical and prognostic significance of eosinophilia and inv(16)/t(16;16) in pediatric acute myelomonocytic leukemia (AML-M4). 61
28371234 2017
24
Presentation of Gallbladder Chloroma in B-Mode Imaging and Contrast-Enhanced Ultrasound (CEUS) in a Patient with Acute Myelomonocytic Leukemia (AML M5). 61
29226275 2017
25
Recurrent somatic JAK-STAT pathway variants within a RUNX1-mutated pedigree. 61
28513614 2017
26
Novel homozygous FANCL mutation and somatic heterozygous SETBP1 mutation in a Chinese girl with Fanconi Anemia. 61
28419882 2017
27
Facial Diplegia as Initial Manifestation of Acute, Myelomonocytic Leukemia with Isolated Trisomy 47, XY,+11[14]/46, XY[6]. 61
28694633 2017
28
Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells. 61
28566492 2017
29
Anthocyanins from black rice (Oryza sativa) promote immune responses in leukemia through enhancing phagocytosis of macrophages in vivo. 61
28672893 2017
30
NUP98 Rearrangement in Acute Myelomonocytic Leukemia With t(11;19)(p15;p12): The First Case Report Worldwide. 61
28224778 2017
31
Sequential strategy for umbilical cord blood transplantation in a Korean Fanconi anemia girl with refractory acute myelomonocytic leukemia and complex karyotype. 61
27976485 2017
32
Cerebral Rhizomucor Infection Treated by Posaconazole Delayed-Release Tablets in an Allogeneic Stem Cell Transplant Recipient. 61
27988409 2017
33
Acute myelomonocytic leukemia and leukocytoclastic vasculitis. 61
28029561 2016
34
Human NUP98-IQCG fusion protein induces acute myelomonocytic leukemia in mice by dysregulating the Hox/Pbx3 pathway. 61
26675333 2016
35
Successful high-dose dexamethasone treatment of acquired pure red cell aplasia following ABO major mismatched allogeneic hematopoietic stem cell transplantation. 61
27384857 2016
36
Leukemia cutis in a patient of relapsed leprosy- Coincidence or predisposition? 61
30212171 2016
37
How Well Do All Patient Refined-Diagnosis-Related Groups Explain Costs of Pediatric Cancer Chemotherapy Admissions in the United States? 61
27118158 2016
38
Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia. 61
26712908 2016
39
Paclitaxel Induced MDS and AML: A Case Report and Literature Review. 61
27057370 2016
40
Identification of a Cryptic Insertion ins(11;X)(q23;q28q12) Resulting in a KMT2A-FLNA Fusion in a 13-Month-Old Child with Acute Myelomonocytic Leukemia. 61
28253492 2016
41
[Cutaneous involvement in chronic myelomonocytic leukemia--a possible indicator for transition into acute leucaemia]. 61
26710205 2016
42
Decreased calcineurin immunoreactivity in the postmortem brain of a patient with schizophrenia who had been prescribed the calcineurin inhibitor, tacrolimus, for leukemia. 61
27462157 2016
43
The Fc-alpha receptor is a new target antigen for immunotherapy of myeloid leukemia. 61
26041304 2015
44
Prognostic factors of childhood and adolescent acute myeloid leukemia (AML) survival: evidence from four decades of US population data. 61
26159683 2015
45
Cytologic findings of hematologic malignancies in bronchoalveolar lavage fluid. 61
31051764 2015
46
A novel mutation of SETBP1 in atypical chronic myeloid leukemia transformed from acute myelomonocytic leukemia. 61
26185647 2015
47
MLL-ELL fusion gene in an acute myelomonocytic leukemia patient transformed from acute promyelocytic leukemia. 61
26185637 2015
48
Bilateral adrenal masses in a patient in remission from acute myelomonocytic leukemia. 61
24566206 2015
49
WEHI-3 cells inhibit adipocyte differentiation in 3T3-L1 cells. 61
25911323 2015
50
The antileukemia roles of PP242 alone or in combination with daunorubicin in acute leukemia. 61
25535978 2015

Variations for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

Expression for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

Search GEO for disease gene expression data for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22).

Pathways for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

Pathways related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.05 MYH11 KIT CSF1R CSF1 CREBBP
2
Show member pathways
12.74 KIT FLT3 CSF1R CSF1 CREBBP
3
Show member pathways
12.7 MYH11 KIT FLT3 CSF1R
4 12.6 RUNX1 KIT FLT3 CSF1R CREBBP
5
Show member pathways
12.55 RUNX1 MPO KIT FLT3 CSF1R CREBBP
6 12.53 KIT FLT3 CSF1R CSF1
7
Show member pathways
12.48 KIT FLT3 CSF1R CSF1
8 11.89 KIT FLT3 CSF1R
9 11.77 MPO KIT FLT3 CSF1
10 11.45 MPO KIT CSF1R CREBBP
11 11.38 RUNX1 MPO KMT2A FLT3 ETV6 CSF1R
12 11.35 KIT FLT3 DNTT CSF1R CSF1
13 11.33 KIT FLT3 CSF1R CSF1
14 11.31 KIT CSF1R CSF1
15
Show member pathways
11.23 CSF1R CSF1 CREBBP
16
Show member pathways
11.12 KIT FLT3
17 10.89 FLT3 ETV6 CREBBP
18 10.78 KIT FLT3 CSF1R CSF1
19 10.73 MPO CSF1
20 10.45 RUNX1 CBFB

GO Terms for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

Cellular components related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 receptor complex GO:0043235 9.33 KIT FLT3 CSF1R
2 core-binding factor complex GO:0016513 8.96 RUNX1 CBFB
3 CSF1-CSF1R complex GO:1990682 8.62 CSF1R CSF1

Biological processes related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.05 RUNX1 KMT2A ETV6 CREBBP CBFB
2 positive regulation of cell proliferation GO:0008284 9.94 KIT FLT3 CSF1R CSF1
3 cytokine-mediated signaling pathway GO:0019221 9.85 KIT FLT3 CSF1R CSF1
4 protein autophosphorylation GO:0046777 9.81 KIT FLT3 CSF1R
5 peptidyl-tyrosine phosphorylation GO:0018108 9.79 KIT FLT3 CSF1R
6 positive regulation of kinase activity GO:0033674 9.7 KIT FLT3 CSF1R
7 hematopoietic progenitor cell differentiation GO:0002244 9.69 KIT FLT3 CSF1R
8 osteoclast differentiation GO:0030316 9.65 CSF1R CSF1
9 regulation of Wnt signaling pathway GO:0030111 9.65 RUNX1 CBFB
10 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.65 KIT FLT3 CSF1R
11 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.64 KIT FLT3
12 macrophage differentiation GO:0030225 9.63 CSF1R CSF1
13 regulation of hematopoietic stem cell differentiation GO:1902036 9.63 RUNX1 KMT2A CBFB
14 positive regulation of macrophage chemotaxis GO:0010759 9.62 CSF1R CSF1
15 regulation of keratinocyte differentiation GO:0045616 9.61 RUNX1 CBFB
16 embryonic hemopoiesis GO:0035162 9.61 KMT2A KIT
17 regulation of megakaryocyte differentiation GO:0045652 9.61 RUNX1 KMT2A CBFB
18 regulation of regulatory T cell differentiation GO:0045589 9.6 RUNX1 CBFB
19 regulation of intracellular estrogen receptor signaling pathway GO:0033146 9.59 RUNX1 CBFB
20 hematopoietic stem cell proliferation GO:0071425 9.58 RUNX1 ETV6
21 regulation of bicellular tight junction assembly GO:2000810 9.58 RUNX1 CBFB
22 regulation of B cell receptor signaling pathway GO:0050855 9.57 RUNX1 CBFB
23 lymphocyte differentiation GO:0030098 9.56 FLT3 CBFB
24 regulation of cytokine-mediated signaling pathway GO:0001959 9.54 RUNX1 CBFB
25 microglial cell proliferation GO:0061518 9.49 CSF1R CSF1
26 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.46 KIT FLT3 CSF1R CSF1
27 myeloid progenitor cell differentiation GO:0002318 9.4 KIT FLT3
28 positive regulation of CD8-positive, alpha-beta T cell differentiation GO:0043378 9.37 RUNX1 CBFB
29 negative regulation of CD4-positive, alpha-beta T cell differentiation GO:0043371 9.32 RUNX1 CBFB
30 macrophage colony-stimulating factor signaling pathway GO:0038145 9.26 CSF1R CSF1
31 hemopoiesis GO:0030097 9.26 RUNX1 KIT FLT3 CSF1R
32 regulation of myeloid cell differentiation GO:0045637 8.8 RUNX1 CREBBP CBFB

Molecular functions related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.03 RUNX1 MYH11 MPO KMT2A KIT FLT3
2 transferase activity GO:0016740 9.8 KMT2A KIT FLT3 DNTT CSF1R CREBBP
3 protein tyrosine kinase activity GO:0004713 9.33 KIT FLT3 CSF1R
4 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 KIT FLT3 CSF1R
5 growth factor binding GO:0019838 8.8 KIT FLT3 CSF1R

Sources for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....